Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Candel Therapeutics Inc

Healthcare US CADL

8.8USD
0.38(4.51%)

Last update at 2026-06-03T20:27:00Z

Day Range

8.329.13
LowHigh

52 Week Range

4.347.66
LowHigh

Fundamentals

  • Previous Close 8.42
  • Market Cap512.73M
  • Volume2087177
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-47.33100M
  • Revenue TTM0.03M
  • Revenue Per Share TTM0.001
  • Gross Profit TTM -23.07400M
  • Diluted EPS TTM-0.72

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -38.18200M -55.17700M -37.93900M -18.79400M -36.12400M
Minority interest - - - - -
Net income -38.18200M -55.17700M -37.93900M -2.86600M -36.12400M
Selling general administrative 17.77M 14.06M 13.72M 14.06M 10.67M
Selling and marketing expenses - - 0.69M - -
Gross profit -0.84500M -0.99000M -23.98000M 0.12M 0.12M
Reconciled depreciation 0.84M 0.99M 0.93M 0.78M 0.23M
Ebit -48.26600M -53.08700M -38.39100M -34.72200M -36.07100M
Ebitda -47.42100M -52.09700M -37.43100M -51.04400M -35.83900M
Depreciation and amortization 0.84M 0.99M 0.96M -16.32200M 0.23M
Non operating income net other - - - - -10.39800M
Operating income -48.26600M -33.37100M -38.39100M -34.72200M -25.72600M
Other operating expenses 48.27M 33.37M 38.39M 34.80M 24.77M
Interest expense 2.12M 2.09M 0.51M 0.49M 0.05M
Tax provision - - - - -
Interest income 3.92M 1.09M 2.08M - -
Net interest income 1.80M -1.00400M -0.03000M -0.49000M -0.05300M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - -15.92800M 10.40M
Total revenue 0.00000M 0.00000M 0.03M 0.12M 0.12M
Total operating expenses 47.42M 32.38M 14.41M 34.80M 25.85M
Cost of revenue 0.84M 0.99M 23.98M - -
Total other income expense net 10.08M -21.80600M 0.45M 15.93M -10.39800M
Discontinued operations - - - - -
Net income from continuing ops -38.18200M -55.17700M -31.92700M -18.79400M -36.12400M
Net income applicable to common shares - - - -18.79400M -36.12400M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 125.19M 106.87M 41.70M 77.69M 89.20M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.66M 1.15M 1.38M 1.89M 2.30M
Total liab 73.27M 40.54M 28.96M 29.98M 25.07M
Total stockholder equity 51.92M 66.33M 12.74M -99.08900M 64.14M
Deferred long term liab - - - - 0.89M
Other current liab 7.42M 26.83M 4.36M 4.63M 3.77M
Common stock 0.55M 0.47M 0.29M 0.29M 0.29M
Capital stock 0.55M 0.47M 0.29M 0.29M 0.29M
Retained earnings -230.38700M -192.20500M -137.02800M -99.08900M -80.29500M
Other liab - - - 2.03M 19.15M
Good will - - - - -
Other assets - - - 0.27M 0.42M
Cash 119.73M 102.65M 35.41M 70.06M 82.64M
Cash and equivalents - - - - -
Total current liabilities 9.00M 37.53M 14.18M 5.62M 5.36M
Current deferred revenue - - - 0.14M -
Net debt -117.82700M -89.18300M -12.65100M -47.25800M -82.08200M
Short term debt 0.45M 10.46M 9.41M 0.46M -
Short long term debt - 9.89M 8.89M - -
Short long term debt total 1.90M 13.47M 22.76M 22.80M 0.56M
Other stockholder equity 281.76M 258.06M 149.48M -0.29000M 144.15M
Property plant equipment - - - 5.48M 3.84M
Total current assets 119.73M 103.80M 36.80M 71.94M 84.94M
Long term investments - - - - -
Net tangible assets - - - 47.71M 64.14M
Short term investments - - - - -
Net receivables - - - - -
Long term debt 47.13M 2.60M 12.38M 20.85M 0.56M
Inventory - - - - -
Accounts payable 1.13M 0.24M 0.42M 0.38M 1.59M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 0.00000M 0.00000M - -89.20500M
Additional paid in capital - - - - -
Common stock total equity - - - - 0.29M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -80.29500M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 5.05M 0.33M 0.12M 0.27M 0.42M
Deferred long term asset charges - - - - -
Non current assets total 5.46M 3.06M 4.91M 5.75M 4.26M
Capital lease obligations 1.90M 0.97M 1.49M 1.95M -
Long term debt total - - - - 0.56M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.01600M -0.52900M -1.29700M -1.83500M
Change to liabilities - - - -1.14600M 0.97M
Total cashflows from investing activities -0.56000M -0.01600M -0.28000M -1.29700M -1.83500M
Net borrowings 36.21M -9.16700M 0.00000M 19.91M 19.91M
Total cash from financing activities 56.10M 94.28M -0.12100M 19.97M 71.80M
Change to operating activities - - - 1.22M -1.42000M
Net income -38.18200M -55.17700M -37.93900M -18.79400M -36.12400M
Change in cash 17.23M 67.24M -34.64500M -12.74200M 47.75M
Begin period cash flow 102.92M 35.68M 70.32M 83.07M 35.32M
End period cash flow 120.15M 102.92M 35.68M 70.32M 83.07M
Total cash from operating activities -38.31100M -27.02300M -34.24400M -31.41900M -22.21800M
Issuance of capital stock 19.37M 101.76M 0.00000M 0.00000M 71.33M
Depreciation 0.84M 0.99M 1.28M 0.78M 0.23M
Other cashflows from investing activities 0.03M - 0.18M - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - -0.12100M - 71.80M
Other cashflows from financing activities 56.10M 1.69M -0.12100M 19.97M 0.47M
Change to netincome - - - -13.76500M 14.46M
Capital expenditures 0.59M 0.02M 0.46M 1.30M 1.83M
Change receivables - - - - -
Cash flows other operating - - - - -1.75200M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - 47.75M
Change in working capital 2.19M 0.35M -0.37800M 0.07M -0.87600M
Stock based compensation 3.82M 5.31M 3.09M 2.31M 2.96M
Other non cash items -6.98400M 21.51M -0.30100M -15.78100M 0.08M
Free cash flow -38.89800M -27.03900M -34.70100M -32.71600M -24.05300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CADL
Candel Therapeutics Inc		 0.38 4.51% 8.80 - 43.48 436.42 10.19 821.98 -0.0084
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Candel Therapeutics Inc

117 Kendrick Street, Needham, MA, United States, 02494

Key Executives

Name Title Year Born
Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D. Pres, CEO & Director 1960
Dr. Estuardo Aguilar-Cordova Inf., M.D., Ph.D. Founder & Director 1958
Ms. Carrie Smith Cox Special Advisor to the CEO 1958
Mr. Jason A. Amello Chief Financial Officer 1968
Dr. Seshu Tyagarajan Ph.D. Chief Technical & Devel. Officer 1967
Dr. Francesca Barone M.D., Ph.D. Chief Scientific Officer 1978
Ms. Ileen B. Winick Chief People Officer NA
Ms. Susan Stewart J.D., L.L.M. Chief Regulatory Officer 1961
Mr. Nathan Caffo Chief Bus. Officer 1969
Dr. William Garrett Nichols M.D., M.S., MS Chief Medical Officer 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions